113 related articles for article (PubMed ID: 8345034)
1. Open dose-finding study of a new potent and selective nonsteroidal aromatase inhibitor, CGS 20 267, in healthy male subjects.
Trunet PF; Mueller P; Bhatnagar AS; Dickes I; Monnet G; White G
J Clin Endocrinol Metab; 1993 Aug; 77(2):319-23. PubMed ID: 8345034
[TBL] [Abstract][Full Text] [Related]
2. Phase I study of the oral nonsteroidal aromatase inhibitor CGS 20267 in healthy postmenopausal women.
Iveson TJ; Smith IE; Ahern J; Smithers DA; Trunet PF; Dowsett M
J Clin Endocrinol Metab; 1993 Aug; 77(2):324-31. PubMed ID: 8345035
[TBL] [Abstract][Full Text] [Related]
3. Specificity of low dose fadrozole hydrochloride (CGS 16949A) as an aromatase inhibitor.
Santen RJ; Demers LM; Lynch J; Harvey H; Lipton A; Mulagha M; Hanagan J; Garber JE; Henderson IC; Navari RM
J Clin Endocrinol Metab; 1991 Jul; 73(1):99-106. PubMed ID: 1646219
[TBL] [Abstract][Full Text] [Related]
4. Phase I study of the oral nonsteroidal aromatase inhibitor CGS 20267 in postmenopausal patients with advanced breast cancer.
Iveson TJ; Smith IE; Ahern J; Smithers DA; Trunet PF; Dowsett M
Cancer Res; 1993 Jan; 53(2):266-70. PubMed ID: 8417819
[TBL] [Abstract][Full Text] [Related]
5. Aromatization mediates testosterone's short-term feedback restraint of 24-hour endogenously driven and acute exogenous gonadotropin-releasing hormone-stimulated luteinizing hormone and follicle-stimulating hormone secretion in young men.
Schnorr JA; Bray MJ; Veldhuis JD
J Clin Endocrinol Metab; 2001 Jun; 86(6):2600-6. PubMed ID: 11397860
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of aromatase with CGS 16949A in postmenopausal women.
Santen RJ; Demers LM; Adlercreutz H; Harvey H; Santner S; Sanders S; Lipton A
J Clin Endocrinol Metab; 1989 Jan; 68(1):99-106. PubMed ID: 2521224
[TBL] [Abstract][Full Text] [Related]
7. A double-blind study of MPV-2213ad, a novel aromatase inhibitor, in healthy male subjects.
Ahokoski O; Irjala K; Huhtala S; Salminen E; Scheinin H; Huupponen R
Eur J Clin Pharmacol; 1999 Mar; 55(1):27-34. PubMed ID: 10206081
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of estrogen biosynthesis and its consequences on gonadotrophin secretion in the male.
Bhatnagar AS; Müller P; Schenkel L; Trunet PF; Beh I; Schieweck K
J Steroid Biochem Mol Biol; 1992 Mar; 41(3-8):437-43. PubMed ID: 1532903
[TBL] [Abstract][Full Text] [Related]
9. Hormonal effects of MPV-2213ad, a new selective aromatase inhibitor, in healthy male subjects. A phase I study.
Ahokoski O; Irjala K; Huupponen R; Halonen K; Salminen E; Scheinin H
Br J Clin Pharmacol; 1998 Feb; 45(2):141-6. PubMed ID: 9491826
[TBL] [Abstract][Full Text] [Related]
10. Arimidex (ZD1033): a selective, potent inhibitor of aromatase in postmenopausal female volunteers.
Yates RA; Dowsett M; Fisher GV; Selen A; Wyld PJ
Br J Cancer; 1996 Feb; 73(4):543-8. PubMed ID: 8595172
[TBL] [Abstract][Full Text] [Related]
11. A phase I study of the pharmacokinetics, pharmacodynamics, and safety of single- and multiple-dose anastrozole in healthy, premenopausal female volunteers.
Tredway DR; Buraglio M; Hemsey G; Denton G
Fertil Steril; 2004 Dec; 82(6):1587-93. PubMed ID: 15589864
[TBL] [Abstract][Full Text] [Related]
12. The efficacy of CGS 20267 in suppressing estrogen biosynthesis in patients with advanced stage breast cancer.
Demers LM; Lipton A; Harvey HA; Kambic KB; Grossberg H; Brady C; Santen RJ
J Steroid Biochem Mol Biol; 1993 Mar; 44(4-6):687-91. PubMed ID: 8476785
[TBL] [Abstract][Full Text] [Related]
13. Phase II study of vorozole (R83842), a new aromatase inhibitor, in postmenopausal women with advanced breast cancer in progression on tamoxifen.
Goss PE; Clark RM; Ambus U; Weizel HA; Wadden NA; Crump M; Walde D; Tye LM; De Coster R; Bruynseels J
Clin Cancer Res; 1995 Mar; 1(3):287-94. PubMed ID: 9815984
[TBL] [Abstract][Full Text] [Related]
14. Aromatase inhibition, testosterone, and seizures.
Harden C; MacLusky NJ
Epilepsy Behav; 2004 Apr; 5(2):260-3. PubMed ID: 15123030
[TBL] [Abstract][Full Text] [Related]
15. Effects of chronic testosterone administration in normal men: safety and efficacy of high dosage testosterone and parallel dose-dependent suppression of luteinizing hormone, follicle-stimulating hormone, and sperm production.
Matsumoto AM
J Clin Endocrinol Metab; 1990 Jan; 70(1):282-7. PubMed ID: 2104626
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetics, pharmacodynamics, safety and tolerability of an intravaginal ring releasing anastrozole and levonorgestrel in healthy premenopausal women: a Phase 1 randomized controlled trial.
Schultze-Mosgau MH; Waellnitz K; Nave R; Klein S; Kraetzschmar J; Rautenberg T; Schmitz H; Rohde B
Hum Reprod; 2016 Aug; 31(8):1713-22. PubMed ID: 27390369
[TBL] [Abstract][Full Text] [Related]
17. ARIMIDEX: a new oral, once-a-day aromatase inhibitor.
Plourde PV; Dyroff M; Dowsett M; Demers L; Yates R; Webster A
J Steroid Biochem Mol Biol; 1995 Jun; 53(1-6):175-9. PubMed ID: 7626450
[TBL] [Abstract][Full Text] [Related]
18. The new aromatase inhibitor CGS-16949A suppresses aldosterone and cortisol production by human adrenal cells in vitro.
Lamberts SW; Bruining HA; Marzouk H; Zuiderwijk J; Uitterlinden P; Blijd JJ; Hackeng WH; De Jong FH
J Clin Endocrinol Metab; 1989 Oct; 69(4):896-901. PubMed ID: 2550511
[TBL] [Abstract][Full Text] [Related]
19. The effects of the aromatase inhibitor anastrozole on bone metabolism and cardiovascular risk indices in ovariectomized, androgen-treated female-to-male transsexuals.
Bunck MC; Toorians AW; Lips P; Gooren LJ
Eur J Endocrinol; 2006 Apr; 154(4):569-75. PubMed ID: 16556720
[TBL] [Abstract][Full Text] [Related]
20. Characterization of anastrozole effects, delivered by an intravaginal ring in cynomolgus monkeys.
Rotgeri A; Korolainen H; Sundholm O; Schmitz H; Fuhrmann U; Prelle K; Sacher F
Hum Reprod; 2015 Feb; 30(2):308-14. PubMed ID: 25432919
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
